Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 28;5:33. doi: 10.1038/s41698-021-00171-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Pearson correlation plots of the eight-gene predictor: AKT2, TSC1, FKB-12, TSC2, RPTOR, RHEB, PIK3CA, and PIK3CB with the PFS of six patients treated with everolimus as monotherapy: one patient out of these six had censored PFS (ID 203). X axis: absolute fold value of log2 based fold-changes tumor versus normal multiplied by log 1.1 based of the intensities in tumor values for each of the eight genes selected; Y axis: PFS under treatment with everolimus as monotherapy in months. b Pearson correlation plots of the eight-gene predictor: AKT2, TSC1, FKB-12, TSC2, RPTOR, RHEB, PIK3CA, and PIK3CB with the PFS of six patients treated with everolimus as monotherapy when only the tumor biopsy is investigated; X axis: absolute fold value of log 1.1 based of the intensities in tumor values for each of the eight genes selected; Y axis: PFS under treatment with everolimus as monotherapy in months. c Shuffle experiment: Pearson correlation plots of the 8 gene specific predictor for everolimus (AKT2, TSC1, FKB-12, TSC2, RPTOR, RHEB, PIK3CA, and PIK3CB) with the PFS of five patients treated with axitinib as monotherapy (Table 1); X axis: absolute fold value of log2 based fold-changes tumor versus normal multiplied by log 1.1 based of the intensities in normal values for each of the eight genes selected; Y axis: PFS under treatment with axitinib as monotherapy in months. d Leave-one-out experiments: each reiteration generates a predictor used to calculate PFS of the patient discarded. e Pearson correlation between leave-one-out predicted PFS and the observed PFS; X axis: predicted PFS as defined by leave-one-out (in months); Y axis: PFS under treatment with everolimus as monotherapy in months observed in WINTHER trial. f Pearson correlation plot for UBAP1 (NAG20) with the PFS of six patients treated with everolimus. X axis: log2 based fold-changes tumor versus normal multiplied by log 1.1 based of the intensities in tumor; Y axis: PFS under treatment with everolimus as monotherapy in months.